Merck will pay a maximum of $37 million to settle all claims against its painkiller Vioxx in Canada.

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

The settlement includes $10 million in costs and fees, and will total between $21.8 million and $37 million, depending upon the number of eligible claims.

The plaintiffs’ lawyer Mike Peerless said up to 2,000 Canadians may be eligible for compensation, adding that the settlement ends a ‘very long and complicated case’.

Bruce Kuhlik, executive vice president of Merck, said: “This agreement is structured to provide certainty and finality toward resolving Vioxx cases in Canada for a fixed amount.

“Under the agreement, there will be an orderly, documented and objective process to examine individual claims to determine qualification.â€

Vioxx (rofecoxib) is believed to have caused tens of thousands of heart attacks and sudden cardiac death between its approval in 1999 and 2004, when Merck removed it from the market.

It was one of the firm’s top selling drugs, but Merck had to pay billions of dollars to settle multiple civil and criminal suits, including a $4.9 billion settlement to cover most of its US cases.

Merck continues to deny any wrongdoing, saying in a statement: “The evidence shows the company acted responsibly with Vioxx, from the careful study in clinical trials … through the careful safety monitoring while Vioxx was on the market, right up through the decision to voluntarily withdraw the medicine in September 2004.â€Â The company added that this settlement “does not constitute any admission of liability.â€

Latest stories

Related stories

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back